Exero Medical

Early Detection of Postoperative Anastomotic Leaks

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in September 2018 by Matan BenDavid, Exero Medical operates with 11–50 employees. The company has raised a total of $16.1M across 5 funding rounds from 8 investors. In February 2025, Exero Medical secured funding from lead investors.

Business overview

Exero Medical is a Health Tech & Life Sciences company focused on developing advanced monitoring solutions for the early detection of postoperative anastomotic leaks following gastrointestinal surgery. Its core product, the xBar monitoring system, utilizes a biodegradable wireless sensor to continuously monitor the anastomosis area, enabling physicians to detect potential leaks and intervene early. The company serves the healthcare industry, specifically targeting surgeons and hospitals to improve patient outcomes and reduce the economic burden associated with complications from GI surgeries.

Strategic signal

In May 2026, Exero Medical announced positive results from its pivotal study, demonstrating the xBar monitoring system's efficacy in the early detection of colorectal surgery complications. This milestone provides significant clinical validation for their technology, signaling to investors and the medical community the potential for improved patient care and reduced post-operative risks in gastrointestinal surgery.

Company Intelligence Q&A

What is Exero Medical's primary focus?
Exero Medical develops advanced monitoring solutions for the early detection of postoperative anastomotic leaks following gastrointestinal surgery.
When did Exero Medical complete enrollment for its US pivotal study?
Exero Medical completed enrollment of its 222-patient US pivotal study for early detection of post-operative gastrointestinal surgery complications in September 2025.
Which investors participated in Exero Medical's February 2025 funding round?
In February 2025, Exero Medical raised funding from lead investors.
When did Exero Medical launch its international pivotal study?
Exero Medical launched its international pivotal study for post-gastrointestinal surgery monitoring in May 2024.
What was a significant regulatory achievement for Exero Medical?
In December 2020, Exero Medical's wireless system for early detection of anastomotic leaks following gastrointestinal surgery received Breakthrough Device Designation from the FDA.

External links